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BACKGROUND AND PURPOSE
Adenosine is considered to be an important modulator of intestinal motility. This study was undertaken to investigate the role
of adenosine in the modulation of contractility in the mouse duodenum and to characterize the adenosine receptor subtypes
involved.
EXPERIMENTAL APPROACH
RT-PCR was used to investigate the expression of mRNA encoding for A1, A2A, A2B and A3 receptors. Contractile activity was
examined in vitro as changes in isometric tension.
KEY RESULTS
In mouse duodenum, all four classes of adenosine receptors were expressed, with the A2B receptor subtype being confined to
the mucosal layer. Adenosine caused relaxation of mouse longitudinal duodenal muscle; this was antagonized by the A1
receptor antagonist and mimicked by N6-cyclopentyladenosine (CPA), selective A1 agonist. The relaxation induced by A1
receptor activation was insensitive to tetrodotoxin (TTX) or Nw-nitro-L-arginine methyl ester (L-NAME). Adenosine also
inhibited cholinergic contractions evoked by neural stimulation, effect reversed by the A1 receptor antagonist, but not
myogenic contractions induced by carbachol. CPA and 2-p-(2-carboxyethyl) phenethylamino-5′-N-ethylcarboxamidoadenosine
hydrochloride hydrate (CGS-21680), A2A receptor agonist, both inhibited the nerve-evoked cholinergic contractions. L-NAME
prevented only the CGS-21680-induced effects. S-(4-Nitrobenzyl)-6-thioinosine, a nucleoside uptake inhibitor, reduced the
amplitude of nerve-evoked cholinergic contractions, an effect reversed by an A2A receptor antagonist or L-NAME.
CONCLUSIONS AND IMPLICATIONS
Adenosine can negatively regulate mouse duodenal motility either by activating A1 inhibitory receptors located
post-junctionally or controlling neurotransmitter release via A1 or A2A receptors. Both receptors are available for
pharmacological recruitment, even if only A2A receptors appear to be preferentially stimulated by endogenous adenosine.
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Introduction
Adenosine is an endogenous nucleoside that can regulate a
large number of physiological and pathophysiological pro-
cesses (Antonioli et al., 2008a). The biological actions of
adenosine are mediated by specific receptors that are currently
distinguished into four subtypes: A1, A2A, A2B and A3 (Fredholm
et al., 2000; Klotz, 2000; nomenclature follows Alexander
et al., 2009). The ability of adenosine to regulate several bio-
logical functions is strictly related to its extracellular concen-
tration. The levels of adenosine at its receptors are determined
by a variety of mechanisms, which include intracellular and
extracellular adenosine biosynthesis, as well as cellular
adenosine release, re-uptake and metabolism (Noji et al.,
2004). Furthermore, extracellular production of adenosine is
increased under adverse conditions, such as hypoxia or
inflammation, and this nucleoside appears to be involved in
mutual interactions between immune/inflammatory cells and
the enteric nervous system, which are responsible for con-
comitant alterations of bowel motility (Antonioli et al.,
2008b). Several lines of evidence highlight a prominent role of
adenosine in the complex interactions between enteric
neurons and smooth muscle, with fine-tuning of motility
effected by this nucleoside. However, the specific function of
adenosine in the regulation of motility in different regions of
the gastrointestinal (GI) tract and in different species has not
been fully clarified. In addition, the location of adenosine
receptors is still controversial. Specifically, for instance, in the
small intestine, exogenous adenosine or related compounds
were found to inhibit cholinergic or tachykininergic transmis-
sion via activation of prejunctional A1 receptors (Shinozuka
et al., 1985; Christofi et al., 1990; Broad et al., 1992; Nitahara
et al., 1995; Tomaru et al., 1995; Coupar, 1999; Lee et al., 2001;
Storr et al., 2002; Duarte-Araújo et al., 2004a; Duarte-Araújo
et al., 2009). The roles of A2 and A3 receptors in the control of
neuromuscular functions in the small bowel are much less
clear. Conflicting evidence has been obtained on A2A receptors,
which have been suggested either to reduce cholinergic motor
responses in guinea-pigs and rats (Gustafsson et al., 1985; Storr
et al., 2002), or to facilitate ACh release in the same species
(Tomaru et al., 1995; Duarte-Araújo et al., 2004a,b). A2B recep-
tors have been shown to be located on the enteric inhibitory
neurons that release NO in mouse distal colon (Zizzo et al.,
2006; Chandrasekharan et al., 2009). A3 receptors have
recently been reported to be expressed in the myenteric
ganglia of rat distal colon and participate in the tonic inhibi-
tory control of excitatory cholinergic motor activity induced
by adenosine (Antonioli et al., 2010). In addition to the
control on myenteric nerves, adenosine has been shown to
exert direct effects on smooth muscle cells in the intestinal
small bowel. Post-junctional inhibitory A1 receptors have been
reported to be present in mouse jejunum and in ileum (De
Man et al., 2003; Zizzo et al., 2009) and in rat duodenum and
ileum (Nicholls et al., 1996; Nicholls and Hourani, 1997). In
addition, stimulation of A2A and A3 receptors has been shown
to inhibit spontaneous contractions in possum duodenum
(Woods et al., 2003), and A2B receptors to mediate relaxation in
rat duodenum (Nicholls et al., 1992; 1996). Thus, our knowl-
edge of the physiological function of adenosine is far from
complete, and more research is required to improve our under-
standing of adenosine-mediated regulation of GI motility and,
also, to consider the possible involvement of adenosine in the
pathophysiology of intestinal disorders.
Hence, this study was undertaken to investigate whether
and which mRNA of adenosine receptor subtypes is expressed
in mouse duodenum and to examine the role of adenosine
receptor activation on duodenal motor function. The results
we obtained suggest that adenosine can negatively regulate
duodenal motility, in mice, either activating A1 inhibitory
receptors located at the post-junctional level or controlling
neurotransmitter release via A1 or A2A receptors located on
enteric nerves.
Methods
All animal care and experimental procedures complied with
the Italian D.L. no. 116 of 27 January 1992 and associated
guidelines in the European Communities Council Directive
of 24 November 1986 (86/609/ECC). Experiments were per-
formed on adult male mice (C57BL/10SnJ; 25.5  0.5 g body
weight; 15 weeks old), obtained from Charles River Labora-
tories (Calco-Lecco, Italy) and maintained in a light- (12 h/
12 h light) and temperature-controlled (23°C) environment
with free access to food and water. Animals were killed by
cervical dislocation, the abdomen was immediately opened
and the duodenum was removed and placed in Krebs solution
consisting of (mM): NaCl 119; KCl 4.5; MgSO4 2.5; NaHCO3
25; KH2PO4 1.2, CaCl2 2.5, glucose 11.1. The contents of the
excised segments were gently flushed out with Krebs solution.
Segments (20 mm in length) were suspended in a four-
channel organ bath containing 10 mL of oxygenated (95% O2
and 5% CO2) Krebs solution maintained at 37°C.
RNA preparation and RT-PCR analysis
Total RNA was extracted from whole thickness duodenum and
in a preparation devoid of mucosa layer, using PureLink™ RNA
Mini Kit (Invitrogen, Paisley, UK) according to the manufac-
turer’s instructions. After quantification by spectrophotom-
etry, 1 mg of total RNA was reverse-transcribed in a final
volume of 50 mL using the High Capacity c-DNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA)
and the following thermal cycle profile: 10 min at 25°C, 2 h at
37°C and 5 min at 85°C as described by the kit. The A1, A2A, A2B,
A3 receptors, b-actin and sucrase isomaltase were amplified
using 100 ng of cDNA per reaction. The oligonucleotide
primers for mouse A1, A2A, A2B, A3 receptors, sucrase isomaltase
and b-actin were as follows: A1: (forward) 5′-TACATCTCGG
CCTTCCAGG-3′, (reverse) 5′-AGTAGGTCTGTGCCCAATG-3′;
A2A: (forward) 5′-GTCCCTGGCCATCATCGT-3′, (reverse) 5′-
GATCCTGTAGGCGTAGAT-3′; A2B: (forward) 5′-TTCCACG
GCTGCCTCTTC-3′, (reverse) 5′-CATCCCCCAGTTCTGTGC-
3′; A3: (forward) 5′-CGTTCCGTGGTCAGTTTG-3′, (reverse)
5′-CGCAGGCGTAGACAATAGG-3′; Sucrase Isomaltase:
(forward) 5′-TTGATATCCGGTCCACGGTTCT-3′, (reverse)
5′-CAGGTGACATCCAGGTTGCATT-3′; b-actin: (forward)
5′-CCGCCCTAGGCACCAGGGT-3′, (reverse) 5′-GGCTGGGG
TGTTGAAGGTCTCAAA-3′. PCR analysis was performed in
triplicate and with the following thermal cycle profile: an
initial step of 45 s at 95°C, an amplification cycle (94°C for
45 s, 55°C for 45 s and 72°C for 1 min) repeated 30 times and
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a final step of 15 min at 72°C. The amplimers were separated
on a 1% agarose gel containing 0.5 mg·mL-1 of ethidium
bromide for visualization, and the gel was scanned under u.v.
light. Expected length of the PCR products for A1, A2A, A2B, A3
receptors and b-actin and sucrase isomaltase were 208, 160,
238, 330, 300 and 143 bp respectively. The corrected band
intensities of the specific adenosine receptors, obtained using
the ImageJ software (U. S. National Institute of Health,
Bethesda, MD, USA), were normalized with the corresponding
b-actin mRNA expression. It was ensured that the band inten-
sities of b-actin mRNA were similar before the comparison of
the expression levels.
Recording of mechanical activity
The distal end of each segment was tied to an organ holder,
and the proximal end was secured with a silk thread to an
isometric force transducer (FORT 10, Ugo Basile, Biological
Research Apparatus, Comerio VA, Italy). Mechanical activity
was digitized on an A/D converter, visualized, recorded and
analysed on a personal computer using the PowerLab/400
system (Ugo Basile, Italy). Longitudinal preparations were
subjected to an initial tension of 200 mg and were allowed to
equilibrate for at least 30 min. Rhythmic spontaneous con-
tractions of varying amplitude developed in all preparations.
After the equilibration time, preparations were challenged
with 0.1 mM isoprenaline or with 10 mM carbachol (CCh) for
2 min, until stable responses were obtained. Concentration–
response curves for adenosine or N6-cyclopentyladenosine
(CPA), an A1 receptor agonist, were constructed by non-
cumulative addition of the drugs. Adenosine or adenosine
receptor agonists were applied for approximately 3 min at
20 min intervals.
The concentration–response curves to adenosine or to the
adenosine receptor agonist were repeated in the presence
of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), an A1
purinoceptor antagonist, 4-(2-[7-amino-2-(2-furyl) [1,2,4]tria-
zolo [2,3-a][1,3,5] triazin-5-ylamino]ethyl)phenol (ZM
241385), an A2A purinoceptor antagonist, or 9-chloro-2-(2-
furanyl)-5-((phenylacetyl) amino)-1,2,4 triazolo 1,5-c
quinazoline (MRS 1220), an A3 purinoceptor antagonist.
Antagonists were in contact with the tissue for at least 30 min
before repeating the dose–response curves for the agonists.
Each preparation was tested with a single antagonist, except
when otherwise stated. Time control experiments showed
that a second curve to the agonists was reproducible. Con-
centrations of the drugs used were determined from literature
and from previous experiments, where they have been
shown, in mouse intestine, to be selective for the receptors
examined (Serio et al., 2003; Zizzo et al., 2005a,b; 2009). The
effects of tetrodotoxin (TTX) or Nw-nitro-L-arginine methyl
ester (L-NAME) were tested against a submaximal dose of
adenosine or CPA.
In a different set of experiments to explore the role of
adenosine receptors in the modulation of cholinergic motor
neurons, electrical field stimulation (EFS) was applied by an
S88 square-wave pulse generator (Grass Medical Instruments,
Quincy, MA, USA) coupled via a stimulus isolation unit (Grass
SIU5) to a pair of platinum electrodes placed in parallel on
either side of the segments. Stimuli of 0.5 ms duration at a
frequency of 4 Hz for 10 s were applied at 5 min intervals.
The voltage was set to produce a submaximal contraction. In
these conditions, the responses to EFS were stable and repro-
ducible for hours. The evoked contractions were abolished by
the muscarinic receptor antagonist, atropine (1 mM), or by
the neuronal blocker, TTX (1 mM), suggesting that they were
mediated by cholinergic nerve activation. The effects of the
purinoceptor agonists, CPA, 2-p-(2-carboxyethyl) phenethy-
lamino-5′-N-ethyl carboxamidoadenosine hydrochloride
hydrate (CGS-21680) or N6-(3-iodobenzyl) adenosine-
5′-N-methyluronamide1-deoxy-1- 6-((3-iodophenyl)methyl)
amino -9H-purin-9-yl-N-methyl-b-D-ribofuranuronamide (IB-
MECA), A1, A2A and A3 receptor agonists, respectively, on the
EFS- evoked contractions were evaluated in the absence and
presence of their respective receptor antagonists.
In order to increase the extracellular levels of adenosine,
preparations were challenged for 20 min with S-(4-
nitrobenzyl)-6-thioinosine (NBTI), a nucleoside uptake
inhibitor. The effects of NBTI on the neural-evoked contrac-
tions were evaluated in the presence of adenosine receptor
antagonists and L-NAME.
Lastly, the effects of the adenosine agonists and antago-
nists were assessed on cholinergic contractions elicited by
direct pharmacological activation of muscarinic receptors
located on smooth muscle cells. Then, colonic preparations
were challenged with CCh (1 mM) in the continuous presence
of TTX (1 mM) in the absence or presence of the different
drugs tested.
Statistical analysis
All data are given as means  SEM; n in the results section
refers to the number of animal preparations on which obser-
vations were made. The amplitude of the relaxation induced
by adenosine or by CPA was measured from the baseline (an
ideal midline between the spontaneous changes of activity)
to the lowest point reached and reported as a percentage of
the effect induced by 0.1 mM isoprenaline. Adenosine or CPA
responses in the absence or presence of the different antago-
nists were fitted to sigmoid curves (Prism 4.0, Graph-PAD, San
Diego, CA), and EC50 values with 95% confidence limits (CLs)
were determined from these curves. Statistical analysis was
performed by means of Student’s t-test or by means of analy-
sis of variance followed by Bonferroni’s test, when appropri-
ate. A probability value of 0.05 was regarded as significant.
Solution and drugs
The drug/molecular target nomenclature (e.g. receptors, ion
channels and so on) used in the present study conforms to
British Journal of Pharmacology’s Guide to Receptors and Chan-
nels (Alexander et al., 2009). The following drugs: adenosine,
CCh, CGS-21680, DPCPX, NBTI, L-NAME, MRS 1220 were all
purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA).
IB-MECA, CPA and ZM 241385 were purchased from Tocris
Bioscience (Bristol, UK), and TTX was from Alomone Labs Ltd
(Jerusalem, Israel). Adenosine, CGS-21680, CPA, DPCPX,
IB-MECA, MRS1220, NBTI and ZM 241385 were dissolved in
dimethyl sulphoxide (DMSO) and further diluted in Krebs.
All the other drugs were dissolved in distilled water. The
maximal final concentration of ethanol and DMSO in the
organ bath was 0.5%, which did not affect the contractility of
the duodenal segments. The working solutions were prepared
fresh on the day of the experiment by diluting the stock
solutions in Krebs and were added to the organ bath.
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Results
Transcripts encoding adenosine receptors in
mouse duodenum
RT-PCR was used to investigate the expression of mRNA
encoding for A1, A2A, A2B and A3 receptors on whole thickness
duodenum and in a mucosa-free preparation. Transcripts
encoding each of the four adenosine receptors were found in
the whole thickness preparations (Figure 1). Indeed, the
preparations devoid of mucosal layer were positive only for
the expected A1, A2A and A3 receptor specific products
(Figure 1). To assess that the preparation was not contami-
nated by mucosa, the presence of transcripts encoding the
mucosal epithelial marker sucrase–-isomaltase was also inves-
tigated. As shown in Figure 1, transcripts encoding the
sucrase–isomaltase were detected only in the whole thickness
sample. The observation that transcripts encoding A2B recep-
tor was only observed in whole thickness samples is consis-
tent with the possibility of the presence of A2B receptor
subtype exclusively in the mucosal layer.
Effects of adenosine and adenosine receptor
agonists on spontaneous mechanical activity
in mouse duodenum
Isolated segments of mouse duodenum displayed spontane-
ous activity characterized by phasic contractions with an
amplitude of 281.4  25.1 mg (n = 30) and a frequency of
38.3  2.8 cpm (n = 30), not modified by TTX (1 mM) or by
atropine (1 mM). Adenosine (0.3–300 mM) produced a relax-
ation that persisted throughout the contact time (Figure 2).
The effect enhanced with the increase in the concentration
and the maximal response at the dose of 300 mM consisted of
a muscular relaxation with an amplitude 70% of the relax-
ation induced by 0.1 mM isoprenaline (EC50, 2.9 mM, 95% CL
2.0–4.4 mM, n = 30) (Figure 2). TTX (1 mM), a blocker of neu-
ronal voltage-dependent Na+ channels, or L-NAME (100 mM),
a blocker of NO synthase, failed to affect the inhibitory effects
induced by a submaximal dose of adenosine (30 mM), indi-
cating that adenosine-induced relaxation was not dependent
on neural action potentials or on endogenous NO production
(Figure 2).
To investigate the receptor(s) responsible for the adenos-
ine inhibitory effects, among the subtypes identified by
RT-PCR in the neuromuscular compartment, we tested the
effect of antagonists for A1, A2A and A3 purinoceptors, DPCPX
(10 nM), ZM 241385 (10 nM) and MRS 1220 (0.1 mM), respec-
tively. Only DPCPX was able to significantly antagonize the
relaxation induced by adenosine, shifting to the right the
dose–response curve to adenosine to the right (EC50, 20.8 mM,
95% CL 9.4–46.9 mM in the presence of DPCPX, n = 5)
(Figure 2). Thus, in our preparation, A1 receptors mediate the
relaxation induced by exogenous adenosine. No additive
effect was observed in the combined presence of A1, A2A and
A3 purinoceptor antagonists.
The inhibitory response to adenosine was mimicked by
the selective A1 receptor agonist CPA, but not by the selective
A2A and A3 receptor agonists, CGS-21680 (up to 5 mM) and
IB-MECA (up to 10 mM), respectively. The inhibitory effects of
CPA (30 nM–30 mM) were antagonized by the selective A1
receptor antagonist, DPCPX (10 nM) (Figure 3). As for
adenosine, neither TTX (1 mM) nor L-NAME (100 mM) affected
the inhibitory effects induced by a submaximal dose of CPA
(3 mM) (Figure 3).
It is noteworthy that none of the antagonists used had
any effect on the spontaneous contractile activity.
Effects of adenosine and adenosine-receptor
agonists on the cholinergic contractions
evoked by EFS and by CCh in
mouse duodenum
EFS (0.5 ms, 4 Hz, submaximal voltage for 10 s) elicited an
early high in amplitude (393.2  15.4 mg, n = 22) cholinergic
contraction. To assess the effect of adenosine on neurally-
Figure 1
Expression of transcripts encoding the adenosine receptor subtypes, A1, A2A, A2B and A3, was analysed in the whole thickness duodenum and in
the mucosa-free preparation. Transcripts encoding each of the four adenosine receptors were detected in the whole thickness preparation. In the
preparations devoid of mucosa layer only, transcripts encoding for A1, A2A and A3 receptor were detected. The mucosal epithelial marker
sucrase–isomaltase was studied to assess the potential contamination of mucosa-free preparation with RNA from the mucosal epithelium. b-Actin
primer was used as a control for cDNA integrity. A 100 bp DNA ladder was used as marker (M).
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evoked cholinergic contractions, a concentration of 1 mM was
chosen since this did not cause a significant reduction of the
spontaneous phasic contraction. Adenosine, at this concen-
tration, was able to inhibit the amplitude of cholinergic
nerve-mediated contractions (Figure 4), without affecting the
direct smooth muscle cholinergic contractions elicited by
10 mM CCh in the presence of TTX (774.8  18.2 mg before
adenosine, 772.9  17.3 mg after adenosine, n = 3, P > 0.05).
Adenosine-induced inhibition of the cholinergic contrac-
tions to EFS was reversed only by the A1 receptor antagonist
DPCPX (10 nM) (Figure 4). CPA at the concentration of
0.1 mM, which did not significantly reduce spontaneous
activity, was able to mimic the inhibitory effects induced by
adenosine, and its effect was antagonized by DPCPX (10 nM),
an A1 receptor antagonist. To further exclude that the possi-
bility that the effects of adenosine or CPA on cholinergic
contractions may be the result of an effect on the baseline
tension, EFS-induced contractions were evoked in the pres-
ence of 1 nM isoprenaline, which per se affected the mechani-
cal activity induced by 1 mM adenosine or 0.1 mM CPA. In
such a condition, cholinergic contractions to EFS were not
affected (from 381.5  10.2 mg to 368.0  9.1 mg in the
presence of 1 nM of isoprenaline, n = 3, P > 0.05). Further-
more, CPA did not affect cholinergic contractions elicited by
10 mM CCh in the presence of TTX (780.1  17.6 mg before
CPA, 777.6  20.5 mg after CPA, n = 3, P > 0.05). Indeed,
CGS-21680, an A2A receptor agonist, which per se did not
affect the spontaneous activity, was inhibited the amplitude
of the EFS-induced cholinergic contractions concentration-
dependently with the maximum effect occurring with 5 mM,
whilst IB-MECA (up to 3 mM) was once more without any
effect (Figure 4). CGS-21680-induced inhibitory effects were
specifically antagonized by the A2A receptor antagonist, ZM
241385 (10 nM) (Figure 4). Moreover, the NO synthase
inhibitor, L-NAME (100 mM), which per se hardly affected
neurally-evoked activity, attenuated only the CGS-21680-
induced inhibitory effects (Figure 5). CGS-21680 did not
affected the cholinergic contractions elicited by 10 mM CCh
in the presence of TTX (791.1  16.6 mg before CGS-21680,
800.3  17.2 mg after CGS-21680, n = 3, P > 0.05). Lastly,
none of the adenosine receptor antagonist per se affected the
cholinergic contractions induced by either CCh or EFS.
Effects of a nucleoside uptake inhibitor
In order to increase the extracellular levels of adenosine,
preparations were challenged with NBTI, a nucleoside uptake
inhibitor. NBTI (10 mM) per se did not significantly modify the
spontaneous mechanical activity but reduced the amplitude
of nerve-evoked cholinergic contractions (Figure 6). The
direct smooth muscle contractions to 10 mM CCh in the
presence of TTX were not modified by NBTI (783.4 12.8 mg
before and 775.7  15.6 mg after NBTI, n = 3, P > 0.05).
NBTI-induced inhibitory effects on neural cholinergic con-
traction were reversed by pretreatment with the A2A receptor
antagonist ZM 241385 (10 nM), but not by DPCPX (10 nM)
or MRS 1220 (0.1 mM), A1 and A3 receptor antagonists,
Figure 2
(A) Original recordings showing the inhibitory response evoked by adenosine (300 mM) in longitudinal duodenal muscular preparations. (B)
Concentration–response curves to adenosine (0.3–300 mM), in the longitudinal duodenal muscular preparations, in the absence or in the presence
of DPCPX (10 nM, n = 5), ZM 241385 (10 nM, n = 4) or MRS 1220 (0.1 mM, n = 4), A1, A2A and A3 receptor antagonists, respectively. (C)
Histograms showing the effects of TTX, a Na+ voltage-gated neural channel blocker (1 mM, n = 4), or L-NAME, an NO synthase inhibitor (100 mM,
n = 5), on the response induced by adenosine (30 mM). Data are means  SEM and are expressed as percentage of the effect induced by 0.1 mM
isoprenaline (Iso). The values for the control curves are the means of the control data obtained before each treatment (n = 13). *P  0.05 when
the concentration–response curves were compared with those obtained in the respective control condition.
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respectively (Figure 6). The NO synthase inhibitor, L-NAME
(100 mM), prevented the inhibition of EFS-induced cholin-
ergic contractions induced by NBTI (Figure 6).
Discussion and conclusions
Adenosine, released by itself from neuronal endings or gen-
erated by breakdown of ATP, is considered to be an important
modulator of intestinal motility in different animal species
(Antonioli et al., 2008b). Adenosine can influence gas-
trointestinal motility either directly, by activating receptors
located on smooth muscle (Serio et al., 1990; Nicholls et al.,
1996; Kadowaki et al., 2000; Woods et al., 2003; Fornai et al.,
2009), or indirectly, by regulating the neurotransmitter
release from enteric neurons (Kadowaki et al., 2000; Lee et al.,
2001; Storr et al., 2002; Duarte-Araújo et al., 2004a,b; Anto-
nioli et al., 2006; Zizzo et al., 2006). The biological actions of
adenosine are mediated by G-protein-coupled receptors cur-
rently distinguished into four subtypes: A1, A2A, A2B and A3
(Fredholm et al., 2000; Klotz, 2000). These receptors are
expressed throughout the gastrointestinal tract, with changes
in the localization and density, depending on the species and
gut region considered (Kadowaki et al., 2000; Christofi et al.,
2001).
Data from our experiments indicate that in mouse duode-
num, the transcripts for all four classes of adenosine receptors
are expressed, and that the A2B receptor subtype is confined to
the mucosal layer. This is in agreement with the postulated
role of adenosine A2B receptors in the autocrine and paracrine
regulation of gastrointestinal secretion (Strohmeier et al.,
1995; Christofi et al., 2001). Whether or not activation of
mucosal A2B receptor may indirectly affect duodenal motility
in the mouse was not investigated in the present study.
In addition, our results highlight a functional role played
by A1 and A2A receptors in the regulation of mouse duodenal
contractility by adenosine. Endogenous adenosine actions
may be restricted to the release/production region at the
intrinsic neural synapse leading to an inhibition of cholin-
ergic transmission, while exogenously added adenosine
seems to activate preferentially extrajunctional inhibitory A1
receptors.
Longitudinal muscle from mouse duodenum, when
mounted in an organ bath, shows spontaneous mechanical
activity, which, differently from ileal segments (Baldassano
et al., 2008; 2009), is not under an excitatory tonic influence
by neurally released ACh. Exogenously added adenosine
caused a concentration-dependent relaxation of mouse lon-
gitudinal duodenal muscle that was antagonized by the selec-
tive A1 receptor antagonist, DPCPX. Our results accord with
those observed in other intestinal preparations, in which
DPCPX at nanomolar concentrations competitively antago-
nizes A1-mediated responses (Nicholls et al., 1996; Kadowaki
et al., 2000). Moreover, CPA, a selective A1 agonist, was able to
mimic the effects of adenosine in a DPCPX-sensitive manner.
Altogether these results indicate that A1 receptors are
involved in the adenosine-induced relaxation of mouse
Figure 3
(A) Original tracing showing the effects of the A1, A2A and A3 receptor agonists, CPA (30 mM), CGS-21680 (5 mM) and IB-MECA (3 mM),
respectively, on spontaneous mechanical activity in the longitudinal muscle of mouse duodenum. (B) Concentration–response curves to CPA in
the absence or in the presence of the A1 receptor antagonist, DPCPX (10 nM, n = 5). (C) Histograms showing the effects of TTX, a Na+
voltage-gated neural channel blocker (1 mM, n = 4), or L-NAME, an NO synthase inhibitor (100 mM, n = 5), on the response induced by CPA
(3 mM). Data are means  SEM and are expressed as percentage of the effect induced by 0.1 mM isoprenaline (Iso). *P  0.05 when the
concentration–response curves were compared with those obtained in the respective control condition.
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longitudinal duodenal muscle. The relaxation induced by A1
receptor activation was not dependent on neuronal action
potentials or on NO synthesis, since it was not modified by
TTX or L-NAME, indicating that A1 receptors are probably
present at the post-junctional level. Post-junctional inhibi-
tory A1 receptors have been reported to be present in rat
duodenum and ileum (Nicholls et al., 1996; Nicholls and
Hourani, 1997), in murine ileum and colon (Zizzo et al.,
2006; 2009) and in the human colon (Fornai et al., 2009). On
the other hand, the relaxant response induced by adenosine
was not modified by selective A2A and A3 receptor antagonists,
per se, or in combination with an A1 receptor antagonist, and
it was not mimicked by the selective A2A and A3 receptor
agonists. Thus, in contrast to the results obtained in possum
duodenum (Woods et al., 2003), A2A and A3 receptors are not
involved in the modulation of spontaneous activity by exog-
enous adenosine in mouse duodenum under our experimen-
tal conditions.
Exogenously administered adenosine was also able to
inhibit the EFS-induced cholinergic contractions. Once
more, this effect is mediated via activation of A1 receptors.
Adenosine, and an A1 receptor agonist, failed to affect the
contractions induced by CCh in the presence of TTX, indi-
cating that the sensitivity of the muscle to muscarinic acti-
vation is not changed and thus suggesting that the
inhibition of EFS-induced cholinergic contractions by
Figure 4
(A) Original tracing showing the effects of adenosine (1 mM) and the A1, A2A and A3 receptor agonists, CPA (0.1 mM), CGS-21680 (5 mM) and
IB-MECA (3 mM), respectively, on the neurally evoked cholinergic contraction (0.5-ms pulse, 4 Hz, submaximal voltage for 10 s) in the longitudinal
muscle of mouse duodenum. (B) Histogram showing the effects induced on the neurally evoked cholinergic contraction by: (i) adenosine (1 mM)
alone or in the presence of the A1, A2A and A3 receptor antagonists DPCPX (10 nM, n = 4), ZM 241385 (10 nM, n = 4) and MRS 1220 (0.1 mM,
n = 3), respectively; (ii) CPA (0.1 mM) alone or in the presence of DPCPX (10 nM, n = 3); (iii) CGS-21680 (5 mM) alone or in the presence of ZM
241385 (10 nM, n = 4). Data are means  SEM and are expressed as a percentage of the amplitude of contraction induced by CCh (10 mM).
*P  0.05 when compared with the respective control.
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adenosine involves a prejunctional mechanism. The obser-
vation that A1 receptor activation is able to reduce EFS-
evoked cholinergic contractions even in the presence of
L-NAME suggests that A1 receptors may be localized on exci-
tatory cholinergic neurons, where they reduce neurotrans-
mitter release, as shown in rat ileum as well as in guinea-pig
ileum and colon and in mouse ileum (Kadowaki et al., 2000;
Lee et al., 2001; Storr et al., 2002; De Man et al., 2003).
Although the effects of exogenous adenosine, at the con-
centrations tested, were not antagonized by an A2A receptor
antagonist, activation of A2A receptors inhibited the EFS-
induced cholinergic contractions, without affecting the
direct muscle cholinergic contraction. This inhibition of the
EFS-induced cholinergic contraction by A2A receptor activa-
tion was antagonized by an NO synthase inhibitor, indicat-
ing that, in mouse duodenum A2A receptors exert their
modulation of cholinergic excitatory pathways through the
generation of NO. This conclusion is in agreement with the
known ability of the nitrergic system to down-regulate ACh
release from myenteric neurons through activation of
guanylyl cyclase (Hebeiss and Kilbinger, 1996; 1998; Mang
et al., 2002), and increments in intracellular calcium con-
centration, required for nNOS activation, can be triggered
by A2A receptors via adenylyl cyclase/cAMP signalling (Fred-
holm et al., 1994). Moreover, A2A receptor modulation of
cholinergic responses by recruitment of intrinsic inhibitory
nitrergic nerves have also been demonstrated in rat and
human colon (Antonioli et al., 2006; 2011; Fornai et al.,
2009). The observation that none of the adenosine receptor
antagonists had any effect on the spontaneous activity or
on the EFS-induce cholinergic contractions suggests that in
mouse duodenum, as reported in ileum and colon (Zizzo
et al., 2006; 2009), the endogenous adenosine level in basal
conditions may be not sufficient to activate the receptors
and thus to be involved in the maintenance of the sponta-
neous and evoked muscular activity.
Since the levels of adenosine at its receptors are determined
by a variety of mechanisms, including cellular adenosine
Figure 5
Histogram showing the effects of pretreatment with L-NAME, an NO
synthase inhibitor (100 mM, n = 5), on the effect induced by adenos-
ine (1 mM), CPA (0.1 mM) or CGS-21680 (5 mM) on the amplitude of
cholinergic contractile responses evoked by EFS (0.5 ms pulse, 4 Hz,
submaximal voltage for 10 s) in the longitudinal muscle of mouse
duodenum. Data are means  SEM and are expressed as a percent-
age of the amplitude of contraction induced by CCh (10 mM). The
values for the control and for L-NAME are the means of the data
obtained before each treatment. *P  0.05 when compared with the
respective control.
Figure 6
Histogram showing the effects induced by the nucleoside uptake
inhibitor, NBTI (10 mM) alone or in the presence of the A1, A2A and A3
receptor antagonists, DPCPX (10 nM, n = 5), ZM 241385 (10 nM,
n = 3), MRS 1220 (0.1 mM, n = 3), or L-NAME, an NO synthase
inhibitor (100 mM, n = 4), on the amplitude of cholinergic contractile
responses evoked by EFS (0.5-ms pulse, 4 Hz, submaximal voltage for
10 s), in the longitudinal muscle of mouse duodenum. Insert: typical
trace showing the effect of NBTI (10 mM) on the amplitude of cho-
linergic contractile responses evoked by EFS (0.5 ms pulse, 4 Hz,
submaximal voltage for 10 s). Data are means  SEM and are
expressed as a percentage of the amplitude of contraction induced
by CCh (10 mM). The values for the control and NBTI are the means
of the data obtained before each treatment. *P  0.05 when com-
pared with the respective control.
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re-uptake (Noji et al., 2004), in order to increase the extracel-
lular level of adenosine, preparations were treated with NBTI,
an adenosine uptake inhibitor. In the presence of NBTI, the
cholinergic contractile response to EFS was decreased, whilst
the amplitude of the spontaneous activity was unchanged.
These effects of NBTI were prevented by antagonism of A2A
receptors, but not of A1 and A3 receptors and by NO synthase
inhibition. Moreover, the direct contractile response to acti-
vation of muscarinic Ach receptors was not modified in the
presence of NBTI. Thus, an increased level of endogenous
adenosine would exert a negative modulation on cholinergic
transmission via activation of A2A receptors probably on intrin-
sic nitrergic neurons. Recently, it has been reported that under
conditions of bowel inflammation, recruitment of A2A recep-
tors by an increased production of endogenous adenosine
enhances the inhibitory control of colonic motility (Antonioli
et al., 2011). Altogether, these findings indicate that nucleo-
side transporters play a role in maintaining the physiological
level of endogenous adenosine limiting its extracellular con-
centration. Endogenous adenosine seems to preferentially
activate only A2A receptors, indicating that, according to the
recent concept of ‘purinome’ (Schwiebert and Fitz, 2008;
Volonté and D’ambrosi, 2009), the mechanism of nucleoside
inactivation and the regional distribution of adenosine recep-
tor subtypes may provide unique conditions for adenosine to
control the excitability of myenteric neurons. The observation
that in the presence of NBTI there was not observed any
modification of spontaneous activity suggests that adenosine
is just released during EFS by enteric interneurons at the
synaptic regions to modulate nitrergic interneurons function
and in turn cholinergic transmission, but not the functionality
of nitrergic motoneurons direct to the muscle.
Lastly, although we also observed the expression of tran-
scripts for A3 receptors in our preparation, in contrast to
findings in the rat distal colon (Antonioli et al., 2010), such
receptors do not seem to play any role in the control of
intestinal motility in mouse duodenum under physiological
conditions. The presence of mRNA for these receptor subtypes
is probably because they are present on cells of the vascular
and immune system that are also included in muscular prepa-
ration (Fredholm et al., 2001). However, the possibility that A3
receptors could have relevant roles in pathological conditions
of the gut, including ischaemia and inflammation, cannot be
excluded. Indeed, in inflammatory bowel disease, an increased
density of functioning and pharmacologically recruitable A3
receptors has been reported, suggesting that activation of
adenosine A3 receptors by selective agonists could represent
suitable tools for the management of those phases of inflam-
matory bowel disease characterized by enhanced motor activ-
ity of the bowel and diarrhea (Antonioli et al., 2010).
In conclusion, under normal conditions, adenosine can
negatively regulate duodenal motility, in mice, either activat-
ing A1 inhibitory receptors located at the post-junctional level
or controlling neurotransmitter release via A1 or A2A receptors
located on enteric nerves. In particular, A1 receptors appear to
act via a direct inhibition of enteric cholinergic nerves, whilst
A2A receptors exert their modulating function on cholinergic
excitatory pathways through the synthesis of NO. Moreover,
both receptors are available for pharmacological recruitment,
even if only A2A receptors appear to be preferentially stimu-
lated by endogenous adenosine.
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